Summary & Overview
CPT 0308U: HART CADhs® Plasma Protein Risk Score
CPT code 0308U designates a Proprietary Laboratory Analyses (PLA) test — HART CADhs® from Prevencio Inc. — that measures three plasma proteins and applies an algorithm to produce a risk score for coronary artery stenosis or obstruction. As a PLA code, 0308U maps to a single manufacturer-specific assay and is used where results may affect diagnostic pathways and downstream care decisions for suspected coronary artery disease.
Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns and benchmarks where available, clarifies clinical context for ordering and interpretation, and summarizes relevant policy implications for laboratory and cardiology service lines.
Readers will learn the clinical purpose of the test, typical sites of service and operational considerations for labs and outpatient providers, and which major payers are included in the coverage review. Data limitations where input fields are incomplete are noted explicitly as "Data not available in the input." The goal is to provide a concise reference for billing, coding, and clinical teams evaluating use of CPT code 0308U in practice.
Billing Code Overview
CPT code 0308U is a Proprietary Laboratory Analyses (PLA) code for the HART CADhs® test from Prevencio Inc. The test assesses a plasma specimen for levels of the three proteins named in the code and uses an algorithmic analysis of those results combined with patient data to generate a risk score for coronary artery stenosis or obstruction. The result is intended to inform clinical decision-making related to coronary artery disease evaluation.
-
Service type: Laboratory diagnostic test using plasma specimen with algorithmic risk scoring
-
Typical site of service: Clinical laboratory or diagnostic lab associated with outpatient care
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with atypical chest pain and multiple cardiovascular risk factors (hypertension, hyperlipidemia, and a family history of premature coronary artery disease) presents to a cardiology clinic. The clinician orders the HART CADhs® proprietary blood test to assist in noninvasive risk stratification for obstructive coronary artery disease. A phlebotomy-trained technician collects a plasma specimen in the outpatient laboratory or hospital outpatient phlebotomy area. The specimen is sent to Prevencio Inc. for analysis. Prevencio measures the three specified plasma proteins, integrates the biomarker values with patient clinical data via the proprietary algorithm, and returns a risk score indicating probability of coronary artery stenosis or obstruction. Results are reviewed by the ordering cardiologist or primary care clinician to inform decisions about further testing (for example, coronary CT angiography, functional stress testing, or invasive coronary angiography) and treatment planning. Typical sites of service include outpatient cardiology clinics, hospital outpatient departments, and independent clinical laboratories performing PLA testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no modifier applies and full global service is reported |
26 |